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Abstract 
Introduction: Type 2 diabetes mellitus (T2DM) affected over 30 million individuals in the United States as of 2015. Due to the national 
diabetes guidelines recommending drug selection based on several patient specific factors and varying formulary restrictions, 
prescribers are often inundated when selecting treatment. Currently, limited evidence is available regarding the primary factors 
influencing prescribers’ drug therapy selection.  
Objectives: The purpose of this study was to identify factors that influence providers during T2DM medication selection. 
Methods: The study was conducted with providers at a large, academic, safety net health system. All prescribers were sent an 
electronic, optional and anonymous survey. Prescribers treating T2DM in non-pregnant adult patients were the only prescribers 
assessed. Factors evaluated were: cost, A1c, comorbidities, adherence, weight, tolerability, patient limitations, and use of guidelines.  
Results: A total of 86 prescribers responded, yielding a response rate of 31%. The respondents included physicians (56.3%), nurse 
practitioners (21.8%), medical residents (18.4%), and fellows (3.4%); with the majority practicing in internal or family medicine (47.1%). 
The most frequently prescribed T2DM medications included: metformin (83.8%), insulin (78.1%), and sulfonylureas (64.8%). Cost and 
A1c elevation were two of the major factors influencing prescribing of metformin (94.1% and 81.2%), insulin (57.4% and 69.6%), and 
sulfonylureas (81.2% and 89.9%) respectively. Due to cost concerns, respondents reported rarely or never prescribing glucagon-like 
peptide-1 agonists (GLP-1RA) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) despite recognizing benefits on diabetes related 
comorbidities.    
Conclusion: Although current literature from the national guidelines encourages the use of GLP-1RA and SGLT2i as first-line options 
after metformin in T2DM, these classes of medications were not reported among the most commonly prescribed despite providers 
correctly identifying positive medication attributes such as cardio- and nephroprotection and weight loss. However, cost of these 
medications appears to outweigh the benefits when selecting medication therapy. 
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Background 
Type 2 diabetes mellitus (T2DM) is a significant health problem 
in the United States. With 30.3 million diabetic cases, 90-95% 
of cases are T2DM with 36.2% of T2DM patients uncontrolled 
on their current regimen. 1,2 The economic impact of T2DM is 
significant, with the annual cost of diagnosed diabetes in 2017 
being $327 billion, a combination of $90 billion in reduced 
productivity and $237 billion in direct medical costs.3 Most 
T2DM patients have at least one other comorbidity; the most 
common comorbidities include: hypertension (82.1%), 
obese/overweight (78.2%), chronic kidney disease (CKD) 
(24.1%), cardiovascular disease (CVD) (21.6%), and heart failure 
(HF) (7.4%).4 The landscape of T2DM management has evolved 
considerably over the last 15 years with over ten antidiabetic 
drug classes available as treatment options.  In addition to new 
therapy, national guidelines are frequently updated with a new 
focus on treatment selection to further manage comorbid 
conditions.5-7 Due to all of these factors, optimal management 
of T2DM is often challenging and complex.  
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Minimal literature exists evaluating how providers weigh 
patient-specific factors to determine drug therapy selection for 
the management of T2DM. In 2007, a national survey of 
physician members of the American Diabetes Association or the 
Society of General Internal Medicine who managed patients 
with T2DM sought to identify the major considerations leading 
to T2DM drug selection. When choosing to initiate drug 
therapy, the top three most common factors considered were: 
assessment of the patient’s health status and comorbid 
conditions (89%), A1c elevation (74%), and patient’s weight 
(66%).8 At the time of this study, national guidelines did not 
have a strong emphasis of drug selection based on 
comorbidities. In addition, dipeptidyl peptidase-4 inhibitors 
(DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-
1RA) were new to the market and sodium-glucose co-
transporter-2 inhibitors (SGLT2i) were not yet available.  
 
More recently, another study evaluated over one million T2DM 
patients to assess changes in prescribing patterns from 2005 to 
2016. During this time, prescribing patterns for monotherapy 
antidiabetic regimens showed an increase in metformin use 
(60% to 77%), a decrease in sulfonylurea (SU) (20% to 8%) and 
thiazolidinedione (TZD) use (11% to 0.7%), while insulin use 
remained consistent (8% to 10%).  Over the course of the study, 
prescribing patterns for add-on therapies showed a decrease in 
SU use (60% to 48%) and an increase in insulin use (7% to 17%). 
Specifically in patients on metformin monotherapy, SU, DPP-4i, 
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and insulin were the most commonly prescribed add-on 
medications.  The newer antidiabetic classes, such as DPP-4i 
(0.4% to 20%), GLP-1RA (3% to 7%), and SGLT2i (0% to 7%) saw 
increased use; however, GLP-1RA and SGLT2i were sub-
optimally used.9   
 
Limitations in the current literature related to prescribing of 
diabetic regimens include changes in available of drug classes, 
knowledge of drug selection to benefit other comorbidities, and 
changes in recommendations from guidelines. With 
approximately one in three patients not being adequately 
controlled on their current diabetes regimen, it is important to 
understand the existing prescribing habits and clinical decision 
making to improve patient care and outcomes. Considering this 
knowledge gap, the purpose of this study was to identify factors 
that influence providers in a large academic safety net health 
system, when selecting antidiabetic medications.  
 
METHODS 
Study Design 
Prescribers from a large academic safety net health system 
located in the Midwest were surveyed on their prescribing 
habits and reasoning for drug selection for the treatment of 
T2DM. The health system has 22 community medical facilities 
with over one million outpatient visits annually serving mainly 
low-income, underserved patients.  The patient population 
treated by the health system is composed of following patient 
demographics:  insurance type includes 37.6% with Medicaid, 
27.3% with Medicare, and 11.3% self-pay; age groups include 
35.8% ages 45-64 years and 23.2% ages 65 years and older; and 
ethnicities include 35.8% African American and 51.9% 
Caucasian.  Nearly 20% of patients seeking treatment within the 
health system are living at or near the federal poverty line.  A 
total of 275 prescribers were eligible to complete the survey; 
this included medical residents, medical fellows, physicians, 
nurse practitioners, and physician assistants. Providers who 
prescribed medications to treat T2DM in non-pregnant adult 
patients were included in the study. Providers working in 
internal or family medicine clinics were considered generalists, 
while providers working in endocrinology, nephrology, 
gerontology, infectious disease (HIV), and others, were 
considered specialists. To minimize the length of time required 
to complete the survey, drug classes such as alpha-glucosidase 
inhibitors, amylin analogs, bile acid sequestrants, and 
meglitinides were excluded, as they are no longer 
recommended for use in the treatment of T2DM. This study was 
approved as exempt by the Institutional Review Board. 
 
Survey 
An optional anonymous electronic 17-question survey was built 
by the research team using the Verient™ survey software and 
distributed via email between November 29th, 2018 and 
December 30th, 2018 with two reminder emails sent to 
improve the response rate during the one-month survey 
period. A link in the email directed prescribers to a cover letter 
describing the study  and allowed for prescribers to give 
consent to participate in the study. Providers were informed 
that the survey will take approximately 10 to 15 minutes. They 
were asked to provide demographic information including their 
professional designation, years of practice, time spent in clinic, 
practice department, geographical location, average time 
between follow-up appointments for T2DM patients, reason for 
this follow-up period, and frequency of time that cost impacted 
drug therapy selection. Prescribers were asked to rank 
(“never”, “rarely”, “often”, “very often”) how frequently they 
prescribed a biguanide, DPP-4i, GLP-1RA, SGLT-2i, TZD, SU, and 
insulin.  In order to assess clinical decision making, providers 
were asked to select “positive”, “negative” or “neutral” 
response for each drug class for each of the following factors: 
cost/insurance coverage, extent of A1c elevation, patient’s 
comorbidities (cardiovascular/renal benefits), patient’s 
adherence (frequency/route of administration), patient’s 
weight/BMI, patient’s tolerability (side effects/adverse drug 
reactions), social/physical/mental limitations, and use of 
guidelines/consensus statements. If the provider selected 
“positive”, this means that the drug is considered beneficial to 
most patients, and vice versa for a “negative” response.  For 
each of the clinical decision-making criteria, prescribers were 
provided a definition of a positive and a negative response.  For 
example, the perception of cost was described a positive if the 
medication was affordable to patients and did not require prior 
authorizations versus negative if the medication was cost 
prohibitive, required prior authorization or was not covered by 
insurances (Appendix 1).  
 
OUTCOMES ANALYSIS 
The primary objective was to assess the positive, neutral, or 
negative perception of each clinical decision-making criteria to 
the respective drug class. The secondary objectives included 
describing the frequency of prescribing type 2 diabetes 
medication classes by providers, comparing the differences in 
clinical decision making between specialists and generalists, 
comparing the differences in clinical decision making between 
providers based on years of practice and comparing the 
differences in clinical decision making between providers based 
on geographical location. 
 
DATA ANALYSIS 
Survey data were imported into SPSSv25.0 (IMB Corp.) software 
for analysis.  Categorical data were summarized using 
frequencies and percentages. Comparison for distributional 
equality were performed using Pearson chi-squared tests or 
Fisher’s exact test depending on cell sample sizes. Post-hoc 
Bonferroni adjusted z-tests were used to detect specific 
distributional differences in the presence of overall 
distributional inequality. Continuous data were summarized 
using means and standard deviations and analyzed for between 
group mean equality using Student’s t-tests.  Unless otherwise 
indicated all statistical testing was two-sided with alpha set at 
0.05. 
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RESULTS 
A total of 86 providers participated in the survey, yielding a 
response rate of 31% (Table 1). The geographical distributions 
of all our respondents were unevenly balanced, with 46.3% of 
providers being from one location. Based on demographic data, 
the responding providers have been practicing for an average 
of 13.85 years and see patients in the office/clinic an average of 
three eight-hour days per week (full time equivalent of 0.58).   
 
Amongst the seven medication classes, metformin (85%), SU 
(78%), and insulin (66%) were prescribed most frequently, 
when combining both “often” and “very often” responses. Four 
drug classes were prescribed infrequently (identified as ‘rarely’ 
or ‘never’ on the survey) included 95.9% (TZD), 91.6% (SGLT2i), 
76.8% (GLP-1RA), and 57.6% (DPP-4i) of the time (Figure 1). The 
most common clinical decision-making factors considered 
when prescribing the most frequently prescribed classes were 
cost and extent of A1c elevation. The selection of metformin, 
insulin, and SU seemed to be largely driven by cost (94.1%, 
56.7%, and 80.9% respectively), and extent of A1c elevation 
(80.9%, 89.7%, and 69.1% respectively). Also, use of 
guidelines/consensus statements was the third reason for 
selection of metformin and insulin (87.3% and 76.2%), versus 
patients’ adherence, which was the third reason for SU 
selection (64.7%) (Table 2).   
 
Some differences noted amongst provider prescribing were 
that specialists identified more positive benefits for SGLT2i (p= 
0.011), while generalists identified more positive benefits for 
SU (p= 0.001). There were no differences seen between 
providers based on years of practice. There were also no 
differences seen based on follow-up appointment time frame 
and drug selection.  Geographical location had no impact on 
drug selection either when compared across all locations or 
when compared at locations with and without the ambulatory 
care pharmacists.  
 
DISCUSSION 
The findings of this study show the complexity involved when 
prescribing drug therapy for T2DM management. This study 
explored most of the key clinical factors recommended by the 
national guidelines. The prescribing habits of the providers 
could be influenced by the ambulatory care pharmacy 
specialists who are being referred approximately one thousand 
patients every year; however, this did not seem to be a 
significant impact based on the statistical analysis.  
 
The use of metformin is very consistent with guideline 
recommendations, and this accentuates the fact the providers 
have an appropriate understanding and utilization of this first-
line medication. The most frequently prescribed medication 
classes (metformin, SU, insulin) were highly viewed as cost 
effective likely due to all these drug classes being represented 
on the 340B formulary utilized at the on-site pharmacies within 
the health system. The importance of cost is known to be a 
major factor nationwide; however it may have been over 
emphasized by providers due to the underserved patient 
population to which they provide care.9  It is important to note 
that while GLP-1RA and SGLT2i were not frequently prescribed 
likely due to a negative association with cost, the drug classes 
were correctly identified as beneficial to patient comorbidities.  
As nearly 25% of T2DM patients have CKD, 20% have CVD and 
8% have heart failure,  utilization of  T2DM medications to also 
benefit these comorbidities is important extremely important 
when selecting therapy for the management of T2DM.4  Based 
on the data from this study, further provider education is 
needed to make providers aware of formulary inclusions for 
Medicaid patients, copay cards for commercial patients, and 
formulary availability of 340b medications that often make 
brand name medications significantly more affordable for 
patients.   
 
This study provides novel insight into the prescribing patterns 
and rationale for antidiabetic regimens.  Compared to prior 
studies, the surveyed prescribers have increased exposure as all 
current antidiabetic medication classes have been on the 
market for at least five years. Also, the recent transition of 
T2DM guidelines to an increased focus on pharmacologic 
intervention based on patient comorbidities and concerns can 
also change prescribing habits.  Although the risk of bias was 
minimized, limitations related to recall bias were possible as 
prescribers may recall primarily their most recent 
interventions.  Selection bias is also possible due to a lack of 
respondents from physician assistants and all respondents 
originating from a single health system. Convenience of the 
survey and short survey length most likely contributed to the 
high response rate. Online surveys of providers have a response 
rate of 11% to 39% with the majority response rates being less 
than 25%.10-12 While the short survey length may have 
increased response rate, minimizing length came at the cost of 
the ability to capture interclass variabilities and assessment of 
other patient factors such as hypoglycemia. 
 
CONCLUSION 
In summary, the most frequently prescribed T2DM medication 
classes at this large academic safety-net hospital were 
metformin, SU, insulin. Cost was a significant driving factor in 
drug selection in the management of T2DM. Based on these 
results, additional provider education should be provided 
regarding updates on national guideline recommendations, 
changes in insurance formularies, and target patient 
populations (comorbidities, weight, hypoglycemia risks) where 
drug selection may differ.  The results of this study should be 
interpreted in the context of the study design and patient 
population/healthcare system, as they may not be 
generalizable to other health care systems. 
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Table 1: Baseline characteristics 
Demographic data for survey participants. 
Demographics Number (%) 
Professional Designation  
Physician 48 (55.8) 
Nurse Practitioner 19 (22.1) 
Resident 16 (18.6) 
Fellow 3 (3.5) 
Practice  
Generalists 57 (66.3) 
Specialist 29 (33.7) 
 
 
 
 
 
Table 2: Clinical Decision-Making Rationale 
Includes the major considerations respondents considered when deciding to prescribe or not prescribe certain T2DM drug classes. 
Clinical decision-making (%) Biguanides DPP-4i GLP-1RA Insulin SGLT2i SU TZD 
 POS NEG POS NEG POS NEG POS NEG POS NEG POS NEG POS NEG 
Cost 94.1 0 20.6 38.2 8.8 64.7 56.7 9 6 65.7 80.9 1.5 22.7 16.7 
Extent of A1c elevation 80.9 1.5 55.9 4.4 68.2 3 89.7 0 33.3 6.1 69.1 4.4 22.4 11.9 
Other comorbidities 73.5 4.4 27.9 1.5 57.4 1.5 42.6 10.3 44.8 9 20.9 16.4 11.8 41.2 
Guideline recommendations 87.3 0 43.3 1.7 50 4.8 76.2 0 32.2 11.3 46 11.1 13.1 36.1 
Weight/BMI 71.9 4.7 15.2 4.7 65.6 1.6 7.9 68.3 21.9 4.7 7.8 48.4 0 41.3 
Adherence 63.2 5.9 66.2 4.4 43.3 13.4 23.5 36.8 32.8 6 64.7 1.5 37.9 6.1 
Limitations 68.3 1.6 43.5 8.1 4.9 36.1 9.7 54.8 22.6 9.7 49.2 0 35.5 6.5 
Patient’s preference 33.3 23.8 50.8 0 25.8 4.8 34.9 14.3 14.3 15.9 30.2 12.7 11.3 40.3 
POS = positive; NEG = Negative 
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Figure 1: Frequency of Prescribed Medications 
 
Includes the frequency at which certain T2DM drug classes where prescribed at the large,  
academic, safety net health system in the Midwest. Ranging from “never” to “very often”. 
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Appendix 1: Survey questionnaire 
The survey questionnaire provided to medical residents, fellows, nurse practitioners, physician assistants, and physicians concerning 
the prescribing of diabetes meditations in the management of T2DM. 
 
1. Do you prescribe medications to treat type 2 diabetes in non-pregnant, adult patients in the outpatient setting? 
a. Yes 
b. No 
2A.  Please select your professional designation. 
a. Fellow 
b. Resident 
c. Certified Nurse Practitioner 
d. Physician Assistant 
e. Physician (MD/DO) 
2B.  Please select your area of specialty 
a. Internal Medicine or Family Medicine 
b. Endocrinology 
c. Geriatrics 
d. Other 
3. How many years have you been in practice? (Round to the nearest full year) ________________ 
4. Which of the following site is your main practice site  (>50% of patient care time) ____________ 
5. What part of an FTE do you spent on direct patient care (0.2FTE = 8 hour day)? ______________ (response 0.1-1 FTE) 
6. How often does cost of the antidiabetic medications, whether due to insurance copay, gap in Medicare coverage, or lack of 
insurance, prevent you from prescribing your preferred Type 2 diabetic regimen for your patients? 
a. Less than 25% 
b. 25-50% 
c. 50-75% 
d. Greater than 75%  
7. On average, how often do you see uncontrolled T2DM patients for follow up? 
e. < 1 month 
f. 1-2 months 
g. 3-4 months 
h. 5-6 months 
i. >6 months 
8. What is the main driving force for this follow-up time frame? 
j. Medication titration 
k. Timing of next HbA1c 
l. Patient request 
m. Availability of provider schedule 
n. Assessment of medication change or patient status 
 
9. How often do you prescribe the following medications in your daily practice? Please select appropriate response for each 
drug class.  Multiple Choice (never, rarely, often, very often). 
*The survey provided through the survey software, after each drug class, the brand and generic names were listed to 
improve correct identification/recognition.  
 
 
 
 
 
 
 
 
 
 
Drug Class Never Rarely Often Very Often 
Biguanides     
DPP4i     
GLP1a     
Insulin     
SGLT2i     
SU     
TZD     
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10. How do you perceive each medication class as it relates to each category?  Please select positive, neutral, or negative for 
each category. For example, positively under medication cost means you think the medication is affordable to most 
patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The survey provided through the survey software, after each drug class, the brand and generic names were listed to 
improve correct identification/recognition. On the survey provided, each category was separated into a different question.  
Consolidated for space considerations.  
 
 Biguanides DPP4i GLP1
a 
Insulin SGLT2
i 
SU TZD 
Cost/Insurance        
Current A1c        
Comorbidity benefit        
Adherence (frequency, route, etc.)        
Guidelines/ Consensus statements/ 
Usual practice 
       
Current weight/ BMI        
Side effects/ Adverse Effects        
Social, physical, or mental limitations        
